普萘洛尔治疗婴幼儿血管瘤的作用机制研究进展

doi:10.19438/j.cjoms.2020.02.019

中国口腔颌面外科杂志 ›› 2020, Vol. 18 ›› Issue (2): 182-185.doi: 10.19438/j.cjoms.2020.02.019

普萘洛尔治疗婴幼儿血管瘤的作用机制研究进展

宋会新, 林春男, 王田友, 付兆臣

哈尔滨医科大学附属第二医院口腔颌面外科,黑龙江哈尔滨 150081

收稿日期:2019-01-04 修回日期:2019-03-25 出版日期:2020-03-20 发布日期:2020-04-30
通讯作者: 付兆臣,E-mail：fuzhaochen@163.com
作者简介:宋会新（1993-）,男,在读硕士研究生,E-mail：971836140@qq.com

Advances in research on the mechanism of propranolol in the treatment of infantile hemangiomas

SONG Hui-xin, LIN Chun-nan, WANG Tian-you, FU Zhao-chen

Department of Oral and Maxillofacial Surgery, Second Affiliated Hospital of Harbin Medical University. Harbin 150081, Heilongjiang Province, China

Received:2019-01-04 Revised:2019-03-25 Online:2020-03-20 Published:2020-04-30

摘要/Abstract

摘要： 婴幼儿血管瘤( infantile hemangioma,IH) 是小儿最常见的良性肿瘤。自 2008 年以来,普萘洛尔逐渐成为IH 的一线治疗药物,但治疗机制尚不完全明了。本文旨在阐述普萘洛尔治疗婴幼儿血管瘤的机制,以便更合理安全地治疗IH。

关键词: 婴幼儿血管瘤, 普萘洛尔, 治疗机制

Abstract: Infantile hemangioma (IH) is the most common benign tumor in children. Since 2008, propranolol has gradually become the first-line treatment for IH, but the treatment mechanism is not completely understood. This paper aimed to elucidate the mechanism of propranolol in the treatment of IH, so as to provide more reasonable and safe treatment for IH.

Key words: Infantile hemangioma, Propranolol, Treatment mechanism

中图分类号:

R739.8

宋会新, 林春男, 王田友, 付兆臣. 普萘洛尔治疗婴幼儿血管瘤的作用机制研究进展[J]. 中国口腔颌面外科杂志, 2020, 18(2): 182-185.

SONG Hui-xin, LIN Chun-nan, WANG Tian-you, FU Zhao-chen. Advances in research on the mechanism of propranolol in the treatment of infantile hemangiomas[J]. China J Oral Maxillofac Surg, 2020, 18(2): 182-185.

参考文献

[1] Phung TL, Hochman M.Pathogenesis of infantile hemangioma[J]. Facial Plast Surg, 2012, 28(6): 554-562.
[2] Léauté-Labrèze C, Dumas de la Roque E, Hubiche T, et al.Propranolol for severe hemangiomas of infancy[J].N Engl J Med, 2008, 358(24): 2649-2651.
[3] Storch CH, Hoeger PH.Propranolol for infantile hemangiomas:insights into the molecular mechanisms of action[J]. Br J Dermatol, 2010, 163(20): 269-274.
[4] Cavalli R, Buffon RB, de Souza M, et al. Tumor lysis syndrome after propranolol therapy in ulcerative infantile hemangioma: rare complication or incidental finding?[J]. Dermatology, 2012, 224(2): 106-109.
[5] Lee D, Boscolo E, Durham JT, et al.Propranolol targets the contractility of infantile haemangioma-derived pericytes[J]. Br J Dermatol, 2014, 171(5): 1129-1137.
[6] Pan WK, Li P, Guo ZT, et al.Propranolol induces regression of hemangioma cells via the down-regulation of the PI3K/Akt/eNOS/VEGF pathway[J]. Pediatr Blood Cancer, 2015, 62(8): 1414-1420.
[7] D'Angelo G, Lee H, Weiner RI. cAMP-dependent protein kinase inhibits the mitogenic action of vascular endothelial growth factor and fibroblast growth factor in capillary endothelial cells by blocking Raf activation[J].J Cell Biochem, 1997, 67(3): 353-366.
[8] Storch CH, Hoeger PH.Propranolol for infantile haemangiomas: insights into the molecular mechanisms of action[J]. Br J Dermatol, 2010, 163(2): 269-274.
[9] Ozeki M, Nozawa A, Hori T, et al.Propranolol for infantile hemangioma: Effect on plasma vascular endothelial growth factor[J]. Pediatr Int, 2016, 58(11): 1130-1135.
[10] 赵忠芳, 吕仁荣, 霍然, 等. 普萘洛尔治疗增生期血管瘤患儿血清中血管内皮生长因子及基质金属蛋白酶9的变化[J]. 中华整形外科杂志, 2011, 27(5): 359-361.
[11] 高健, 徐潇. 普萘洛尔对婴幼儿血管瘤患者尿液中基质金属蛋白酶(MMPs)表达水平的影响[J]. 中国美容整形外科杂志, 2017, 28(5): 299-301.
[12] Bokoch MP, Zou Y, Rasmussen SG, et al.Ligand-specific regulation of the extracellular surface of a G-protein-coupled receptor[J]. Nature, 2010, 463(7277): 108-112.
[13] de Jong S, Itinteang T, Withers AH, et al. Does hypoxia play a role in infantile hemangioma?[J]. Arch Dermatol Res, 2016,308(4): 219-227.
[14] 杨艳萍, 张国珍, 张云艳. DLL4蛋白在恶性肿瘤中的研究进展[J]. 现代肿瘤医学, 2016, 24(22): 3687-3690.
[15] Sun B, Dong C, Lei H, et a1. Propranolol inhibits proliferation and invasion of hemangioma-derived endothelialcells by suppressing the DLL4/Notch1/Akt pathway[J]. Chem Biol Interact, 2018, 18(24): 28-33.
[16] Li S, Xu G, Gao F, et al.Expression and association of VEGF-Notch pathways in infantile hemangiomas[J]. Exp Ther Med, 2017, 14(4): 3737-3743.
[17] Li D, Li P, Guo Z, et al.Downregulation of miR-382 by propranolol inhibits the progression of infantile hemangioma via the PTEN-mediated AKT/mTOR pathway[J]. Int J Mol Med, 2017, 39(3): 757-763.
[18] 凌彬, 陈曼丽, 刘洁, 等. 普萘洛尔治疗增殖期血管瘤患者血管内皮生长因子A及表皮生长因子样结构域7 的表达分析[J]. 华西口腔医学杂志, 2014, 32(5): 441-445.
[19] 周昱川. 色素上皮衍生因子在普萘洛尔治疗婴幼儿血管瘤中的作用机制[D]. 乌鲁木齐:新疆医科大学, 2017.
[20] Itinteang T, Marsh R, Davis PF, et al.Angiotensin Ⅱ causes cellular proliferation in infantile haemangioma via angiotensin Ⅱ receptor 2 activation[J]. J Clini Pathol, 2015, 68(5): 346-350.
[21] 范桂权. CD39在普萘洛尔治疗血管瘤裸鼠模型中的作用机制探讨[D]. 泸州:泸州医学院, 2013.
[22] 何辉霞. 普萘洛尔诱导血管内皮细胞凋亡对P38MAPK信号通路影响的体外实验研究[D]. 泸州:泸州医学院, 2014.
[23] Tu JB, Ma RZ, Dong Q, et al.Induction of apoptosis in infantile hemangioma endothelial cells by propranolol[J]. Exp Ther Med, 2013, 6(2): 574-578.
[24] Wong A, Hardy KL, Kitajewski AM, et al.Propranolol accelerates adipogenesis in hemangioma stemcells and causes apoptosis of hemangioma endothelial cells[J]. Plast Reconstr Surg, 2012, 130(5): 1012-1021.
[25] England RW, Hardy KL, Kitajewski AM, et al.Propranolol promotes accelerated and dysregulated adipogenesis in hemangioma Stemclls[J]. Ann Plast Surg, 2014, 73(1): 119-124.
[26] Yao TH, Pataer P, Regmi KP, et al.Propranolol induces hemangioma endothelial cell apoptosis via a p53-BAX mediated pathway[J]. Mol Med Rep, 2018, 18(1): 684-694.
[27] Ma XR, Zhao TH, Ouyang TX, et al.Propranolol enhanced adipogenesis instead of induction of apoptosis of hemangiomas stem cells[J]. Int J Clin Exp Pathol, 2014, 7(7): 3809-3817.

普萘洛尔治疗婴幼儿血管瘤的作用机制研究进展

Advances in research on the mechanism of propranolol in the treatment of infantile hemangiomas

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	郑家伟, 王绪凯, 秦中平, 范新东, 李凯, 杨耀武, 霍然, 刘少华, 赵吉宏, 汪小勇, 周德凯, 刘学键. 口服普萘洛尔治疗婴幼儿血管瘤中国专家共识（2022版）[J]. 中国口腔颌面外科杂志, 2022, 20(4): 313-319.
[2]	郑家伟, 赵泽亮, 陈启铭. 婴幼儿血管瘤循证治疗现状[J]. 中国口腔颌面外科杂志, 2022, 20(1): 7-14.
[3]	王杞章, 郑家伟. 口服普萘洛尔治疗婴幼儿增殖期血管瘤:英国儿科皮肤病学会共识及临床指南[J]. 中国口腔颌面外科杂志, 2020, 18(6): 548-552.
[4]	顾达, 霍然, 徐广琪, 毕见海, 李尚滨. 局部外用β受体阻滞剂治疗婴幼儿血管瘤的临床应用研究进展[J]. 中国口腔颌面外科杂志, 2020, 18(4): 375-380.
[5]	李红, 周昱川, 龚忠诚, 孙杨, 凌彬. 口服普萘洛尔联合外用盐酸倍他洛尔治疗8例眶周高风险婴幼儿血管瘤的疗效和安全性评价[J]. 中国口腔颌面外科杂志, 2020, 18(3): 264-268.
[6]	刘学键, 刘志鹏, 武宜雷, 邰茂众. 平阳霉素新剂型瘤体内注射治疗婴幼儿血管瘤203例临床分析[J]. 中国口腔颌面外科杂志, 2019, 17(3): 247-250.
[7]	刘诗奇, 羊良慧, 陈国生, 王辉, 房芳, 廖显翔, 麦华明. β肾上腺素受体在舌癌CAL-27细胞系的表达及β受体阻滞剂对其增殖、迁移、侵袭的影响[J]. 中国口腔颌面外科杂志, 2018, 16(5): 391-396.
[8]	张凯驰, 徐大朋, 程沫沙, 王绪凯. 马来酸噻吗洛尔和普萘洛尔治疗婴幼儿表浅型血管瘤的疗效分析[J]. 中国口腔颌面外科杂志, 2017, 15(6): 529-533.
[9]	周昱川，凌彬，龚忠诚，许颖捷，陈青立. 外涂盐酸倍他洛尔滴眼液治疗7例表浅型婴幼儿血管瘤疗效观察[J]. 中国口腔颌面外科杂志, 2017, 15(5): 438-441.
[10]	程沫沙，张凯驰，王绪凯. 普萘洛尔治疗溃疡性婴幼儿血管瘤18例临床分析[J]. 中国口腔颌面外科杂志, 2017, 15(3): 264-267.
[11]	赵志国, 潘遥, 杨东升, 张力平. 口服普萘洛尔治疗婴幼儿鼻部血管瘤临床疗效评价[J]. 中国口腔颌面外科杂志, 2017, 15(2): 147-152.
[12]	赵志国, 潘遥, 杨东升, 张力平. 口服普萘洛尔治疗婴幼儿鼻部血管瘤临床疗效评价[J]. 中国口腔颌面外科杂志, 2017, 15(2): 161-164.
[13]	董建勇, 李凯, 岳琳琳, 李荣慧, 黄莹莹, 刘少华. 口服普萘洛尔对血管瘤患儿体格发育的近期影响[J]. 中国口腔颌面外科杂志, 2016, 14(6): 510-513.
[14]	王菲楠, 范新东. 放射性核素治疗婴幼儿血管瘤的现状[J]. 中国口腔颌面外科杂志, 2016, 14(5): 471-474.
[15]	薛雷, 刘子玫, 徐大朋, 佟爽, 程晨, 宫贺, 王绪凯. 口服普萘洛尔治疗婴幼儿眶周血管瘤临床疗效观察[J]. 中国口腔颌面外科杂志, 2016, 14(2): 140-143.